It is the consensus opinion of the Medical Oncology Reference Committee that this protocol is not considered best practice for this patient population as there is no clinical need.
Treatment Schedule Summary
Cycle 1
Drug |
Dose |
Route |
Day |
nab- PACLitaxel |
100 mg/m2 * |
IV infusion |
1, 8, 15, 29, 36, 43, 57, 64, 71 |
Trastuzumab |
8 mg/kg (loading dose only) |
IV infusion ** |
1 |
Trastuzumab |
6 mg/kg (subsequent doses) |
IV infusion ** |
22, 43, 64 |
Cycle 2 and further cycles
Drug |
Dose |
Route |
Day |
nab- PACLitaxel |
100 mg/m2 * |
IV infusion |
1, 8, 15, 29, 36, 43, 57, 64, 71 |
Trastuzumab |
6 mg/kg (subsequent doses) |
IV infusion ** |
22, 43, 64 |
*Consider nab-paclitaxel 125 mg/m2 in fit patients receiving 1st line treatment
**Trastuzumab is available as a subcutaneous formulation administered at a dose of 600 mg every three weeks. Subcutaneous trastuzumab has a similar safety profile to intravenous trastuzumab and is non-inferior in terms of pharmacokinetic profile and efficacy and therefore is a valid alternative route of administration compared to standard intravenous trastuzumab. Link to Breast trastuzumab subcutaneous protocol
Frequency: every 84 days
Cycle: Continuous until disease progression or unacceptable toxicity